Related Experiment Video
Updated: Mar 25, 2026

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
Published on: December 13, 2018
Short and Long Non-Coding RNAs in Renal Cell Carcinoma
Monia Cecati1, Valentina Pozzi2, Valentina Schiavoni2
1Department of Human Sciences and Promotion of the Quality of Life, San Raffaele Roma University, 00166 Rome, Italy.
Abstract:
Renal cell carcinoma (RCC) represents the most frequent kidney malignancy and remains a major clinical challenge due to its often silent onset, high metastatic potential, and limited responsiveness to conventional chemotherapy. Increasing evidence indicates that non-coding RNAs (ncRNAs), including microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and circular RNAs (circRNAs), are key regulators of RCC tumorigenesis, progression, and therapy resistance. Rather than providing a purely descriptive overview, this review focuses on emerging mechanistic paradigms through which ncRNAs actively shape tumor behavior and therapeutic response in RCC. This review summarizes current knowledge on the biological and clinical relevance of ncRNAs in RCC, highlighting their dual roles as oncogenic drivers or tumor suppressors through the modulation of pathways involved in proliferation, apoptosis, angiogenesis, invasion, immune evasion, metabolic reprogramming, and ferroptosis. Particular emphasis is placed on mechanistically defined ncRNA regulatory axes controlling ferroptosis, autophagy, metabolic reprogramming, and immune escape, as well as on ncRNA-mediated intercellular communication via extracellular vesicles, which promotes the dissemination of resistance to targeted therapies. The review also addresses ncRNA-based diagnostic and prognostic applications, including miRNA signatures capable of discriminating RCC subtypes and circulating ncRNAs as minimally invasive biomarkers. Moreover, the manuscript discusses ncRNA-mediated mechanisms of resistance to targeted therapies such as sunitinib, sorafenib, and axitinib, emphasizing regulatory networks involving miRNA targets, lncRNA-miRNA sponging, RNA-binding proteins, extracellular vesicle transfer, and epigenetic modulation. Emerging therapeutic opportunities are also addressed, including strategies aimed at inhibiting oncogenic ncRNAs or restoring tumor-suppressive ncRNAs to enhance drug sensitivity and improve patient stratification.
Insights
Non-coding RNAs (ncRNAs) are key regulators in kidney cancer (RCC), driving tumor growth and therapy resistance. Understanding these ncRNA mechanisms offers new diagnostic, prognostic, and therapeutic strategies for renal cell carcinoma.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Renal cell carcinoma (RCC) is a prevalent kidney cancer with poor outcomes due to late detection and treatment resistance.
- Non-coding RNAs (ncRNAs), including microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and circular RNAs (circRNAs), are increasingly recognized as critical players in RCC.
- Dysregulation of ncRNAs influences RCC initiation, progression, metastasis, and response to therapy.
Purpose of the Study:
- To review the mechanistic roles of ncRNAs in renal cell carcinoma (RCC) pathogenesis and therapeutic resistance.
- To highlight the dual functions of ncRNAs as oncogenes or tumor suppressors in RCC.
- To discuss the potential of ncRNAs as diagnostic, prognostic, and therapeutic targets in RCC.
Main Methods:
- Literature review focusing on mechanistic studies of ncRNAs in RCC.
- Analysis of ncRNA involvement in key cancer pathways: proliferation, apoptosis, angiogenesis, invasion, immune evasion, metabolic reprogramming, and ferroptosis.
- Examination of ncRNA-mediated resistance to targeted therapies and intercellular communication via extracellular vesicles.
Main Results:
- ncRNAs actively modulate RCC behavior, acting as oncogenic drivers or tumor suppressors.
- Specific ncRNA regulatory axes control ferroptosis, autophagy, metabolism, and immune escape in RCC.
- ncRNAs contribute to targeted therapy resistance through various mechanisms, including sponging and extracellular vesicle transfer.
Conclusions:
- ncRNAs are pivotal in RCC tumorigenesis, progression, and drug resistance.
- ncRNA signatures show promise for RCC diagnosis and prognosis.
- Targeting ncRNAs presents novel therapeutic avenues for enhancing drug sensitivity and patient stratification in renal cell carcinoma.
Related Concept Videos
lncRNA - Long Non-coding RNAs
lncRNA - Long Non-coding RNAs
Non-LTR Retrotransposons
Types of RNA
RNA Performs Diverse...
Types of RNA
Three main types of RNA are involved in protein synthesis: messenger RNA (mRNA), transfer RNA (tRNA), and ribosomal RNA (rRNA). These RNAs perform diverse functions and can be broadly classified as protein-coding or non-coding RNA. Non-coding RNAs play important roles in the regulation of gene expression in response to developmental and environmental changes. Non-coding RNAs in prokaryotes can be manipulated to develop more effective antibacterial drugs for human or animal use.
RNA...
MicroRNAs
